Loading clinical trials...

Phendimetrazine and Cocaine | Clinical Trials | Clareo Health

COMPLETEDEARLY_PHASE1

Phendimetrazine and Cocaine

Safety and Tolerability of Cocaine During Phendimetrazine Maintenance

NCT02233647•William Stoops

Summary

This study will determine the safety and tolerability of phendimetrazine (Bontril®) as a pharmacotherapy for cocaine use disorder. A rigorous, inpatient human laboratory study will be conducted in which the subjective and physiological effects of cocaine are evaluated during maintenance on placebo and phendimetrazine.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Recent cocaine use

Exclusion Criteria

•Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant
•Current or past histories of substance abuse or dependence that are deemed by the study physicians to interfere with study completion
•History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation
•Females not currently using effective birth control
•Contraindications to cocaine or phendimetrazine

Locations (1)

University of Kentucky Laboratory of Human Behavioral Pharmacology

Lexington, Kentucky, United States

Key Dates

Start Date

September 1, 2014

Primary Completion Date

December 1, 2015

Completion Date

December 1, 2015

Last Updated

September 27, 2017

Enrollment

ACTUAL participants

Conditions

Cocaine Use Disorder

Interventions

Cocaine

DRUG

Placebo

DRUG

Web-based Alcohol- or Cocaine-specific Inhibition Training in Adolescents and Young Adults With Substance Use Disorder

NCT07071779

Alcohol Use Disorder (AUD)Cocaine Use Disorder (CUD)+1 more

View study

RECRUITING

Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study

NCT04721418

Cocaine Use DisorderHealthy Controls

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 27, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phendimetrazine and Cocaine

Inclusion Criteria

Exclusion Criteria

Web-based Alcohol- or Cocaine-specific Inhibition Training in Adolescents and Young Adults With Substance Use Disorder

Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study

Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction

rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder

rTMS for Stimulant Use Disorders

A Study to Investigate the Interaction Between TMP-301 and Cocaine.